{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:38:47Z","timestamp":1791376727370,"version":"4.3.2"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,2]]},"DOI":"10.7759\/cureus.33242","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T04:07:04Z","timestamp":1672632424000},"source":"Crossref","is-referenced-by-count":39,"title":["An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis"],"prefix":"10.7759","author":[{"given":"Ibrahim M","family":"Dighriri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahood A","family":"Aldalbahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah","family":"Albeladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asimah A","family":"Tahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaf M","family":"Kinani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rand A","family":"Almohsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouf H","family":"Alamoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer A","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan J","family":"Alkhamshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha A","family":"Althomali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan N","family":"Alrubaiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal K","family":"Altowairqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2016.06.016","article-title":"Epidemiology of multiple sclerosis","volume":"34","author":"Howard J","year":"2016","unstructured":"Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016, 34:919-39. 10.1016\/j.ncl.2016.06.016","journal-title":"Neurol Clin"},{"key":"ref2","article-title":"Impact of diagnosis and early treatment on the course of multiple sclerosis","volume":"19","author":"Noyes K","year":"2013","unstructured":"Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care. 2013, 19:s321-31.","journal-title":"Am J Manag Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24747","article-title":"Long-term evolution of multiple sclerosis disability in the treatment era","volume":"80","author":"Cree BA","year":"2016","unstructured":"Cree BA, Gourraud PA, Oksenberg JR, et al.. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016, 80:499-510. 10.1002\/ana.24747","journal-title":"Ann Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-052920-040318","article-title":"The immune response in multiple sclerosis","volume":"17","author":"Rodr\u00edguez Mur\u00faa S","year":"2022","unstructured":"Rodr\u00edguez Mur\u00faa S, Farez MF, Quintana FJ. The immune response in multiple sclerosis. Annu Rev Pathol. 2022, 17:121-39. 10.1146\/annurev-pathol-052920-040318","journal-title":"Annu Rev Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70267-4","article-title":"Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses","volume":"14","author":"Belbasis L","year":"2015","unstructured":"Belbasis L, Bellou V, Evangelou E, Ioannidis JPA, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015, 14:263-73. 10.1016\/S1474-4422(14)70267-4","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(02)00396-X","article-title":"Cytokine profile in patients with multiple sclerosis following vitamin D supplementation","volume":"134","author":"Mahon BD","year":"2003","unstructured":"Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol. 2003, 134:128-32. 10.1016\/S0165-5728(02)00396-X","journal-title":"J Neuroimmunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold R","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al.. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012, 367:1098-107. 10.1056\/NEJMoa1114287","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-6-s53","article-title":"Multiple sclerosis, a treatable disease","volume":"16","author":"Doshi A","year":"2016","unstructured":"Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016, 16:s53-9. 10.7861\/clinmedicine.16-6-s53","journal-title":"Clin Med (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102162","article-title":"A literature review of cost-of-illness studies on the economic burden of multiple sclerosis","volume":"43","author":"Paz-Zulueta M","year":"2020","unstructured":"Paz-Zulueta M, Par\u00e1s-Bravo P, Cantarero-Prieto D, Bl\u00e1zquez-Fern\u00e1ndez C, Oterino-Dur\u00e1n A. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020, 43:102162. 10.1016\/j.msard.2020.102162","journal-title":"Mult Scler Relat Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2016.0355","article-title":"Effects of acupuncture on gait of patients with multiple sclerosis","volume":"23","author":"Criado MB","year":"2017","unstructured":"Criado MB, Santos MJ, Machado J, Gon\u00e7alves AM, Greten HJ. Effects of acupuncture on gait of patients with multiple sclerosis. J Altern Complement Med. 2017, 23:852-7. 10.1089\/acm.2016.0355","journal-title":"J Altern Complement Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(09)70003-6","article-title":"The history of multiple sclerosis: the changing frame of the disease over the centuries","volume":"277","author":"Murray TJ","year":"2009","unstructured":"Murray TJ. The history of multiple sclerosis: the changing frame of the disease over the centuries. J Neurol Sci. 2009, 277:S3-8. 10.1016\/S0022-510X(09)70003-6","journal-title":"J Neurol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0306-9877(88)90023-0","article-title":"Multiple sclerosis is a chronic central nervous system infection by a spirochetal agent","volume":"25","author":"Marshall V","year":"1988","unstructured":"Marshall V. Multiple sclerosis is a chronic central nervous system infection by a spirochetal agent. Med Hypotheses. 1988, 25:89-92. 10.1016\/0306-9877(88)90023-0","journal-title":"Med Hypotheses"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/377150a0","article-title":"A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group","volume":"377","author":"Ebers GC","year":"1995","unstructured":"Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature. 1995, 377:150-1. 10.1038\/377150a0","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1353\/pbm.2005.0079","article-title":"The emergence of multiple sclerosis, 1870-1950: a puzzle of historical epidemiology","volume":"48","author":"Talley CL","year":"2005","unstructured":"Talley CL. The emergence of multiple sclerosis, 1870-1950: a puzzle of historical epidemiology. Perspect Biol Med. 2005, 48:383-95. 10.1353\/pbm.2005.0079","journal-title":"Perspect Biol Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91611-9","article-title":"Is multiple sclerosis caused by an oral spirochaete?","volume":"328","author":"Gay D","year":"1986","unstructured":"Gay D, Dick G. Is multiple sclerosis caused by an oral spirochaete?. Lancet. 1986, 328:75-7. 10.1016\/S0140-6736(86)91611-9","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin FD","year":"1996","unstructured":"Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996, 46:907-11. 10.1212\/wnl.46.4.907","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.54.5.1145","article-title":"Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group","volume":"54","author":"Rice GP","year":"2000","unstructured":"Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000, 54:1145-55. 10.1212\/wnl.54.5.1145","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0025-4","article-title":"Therapeutic targeting of trained immunity","volume":"18","author":"Mulder WJM","year":"2019","unstructured":"Mulder WJM, Ochando J, Joosten LAB, Fayad ZA, Netea MG. Therapeutic targeting of trained immunity. Nat Rev Drug Discov. 2019, 18:553-66. 10.1038\/s41573-019-0025-4","journal-title":"Nat Rev Drug Discov"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70094-6","article-title":"Multiple sclerosis: risk factors, prodromes, and potential causal pathways","volume":"9","author":"Ramagopalan SV","year":"2010","unstructured":"Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010, 9:727-39. 10.1016\/S1474-4422(10)70094-6","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115972","article-title":"Clustering of residence of multiple sclerosis patients at age 13 to 20 years in Hordaland, Norway","volume":"133","author":"Riise T","year":"1991","unstructured":"Riise T, Gr\u00f8nning M, Klauber MR, Barrett-Connor E, Nyland H, Albrektsen G. Clustering of residence of multiple sclerosis patients at age 13 to 20 years in Hordaland, Norway. Am J Epidemiol. 1991, 133:932-9. 10.1093\/oxfordjournals.aje.a115972","journal-title":"Am J Epidemiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-016-0688-8","article-title":"Diagnostic criteria, classification and treatment goals in multiple sclerosis: the chronicles of time and space","volume":"16","author":"Ntranos A","year":"2016","unstructured":"Ntranos A, Lublin F. Diagnostic criteria, classification and treatment goals in multiple sclerosis: the chronicles of time and space. Curr Neurol Neurosci Rep. 2016, 16:90. 10.1007\/s11910-016-0688-8","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2011.240432","article-title":"Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis","volume":"82","author":"Simpson S Jr","year":"2011","unstructured":"Simpson S Jr, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011, 82:1132-41. 10.1136\/jnnp.2011.240432","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-017-0086-4","article-title":"Vitamin D and multiple sclerosis: a comprehensive review","volume":"7","author":"Sintzel MB","year":"2018","unstructured":"Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Ther. 2018, 7:59-85. 10.1007\/s40120-017-0086-4","journal-title":"Neurol Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.245462","article-title":"The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging","volume":"14","author":"Guan Y","year":"2019","unstructured":"Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B, Zivadinov R. The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regen Res. 2019, 14:373-86. 10.4103\/1673-5374.245462","journal-title":"Neural Regen Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt356","article-title":"Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden","volume":"137","author":"Westerlind H","year":"2014","unstructured":"Westerlind H, Ramanujam R, Uvehag D, et al.. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain. 2014, 137:770-8. 10.1093\/brain\/awt356","journal-title":"Brain"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1932604100","article-title":"Twin concordance and sibling recurrence rates in multiple sclerosis","volume":"100","author":"Willer CJ","year":"2003","unstructured":"Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A. 2003, 100:12877-82. 10.1073\/pnas.1932604100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029819","article-title":"Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations","volume":"7","author":"Alcina A","year":"2012","unstructured":"Alcina A, Abad-Grau Mdel M, Fedetz M, et al.. Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS One. 2012, 7:e29819. 10.1371\/journal.pone.0029819","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2018.01.007","article-title":"A review on potential roles of vitamins in incidence, progression, and improvement of multiple sclerosis","volume":"10","author":"Khosravi-Largani M","year":"2018","unstructured":"Khosravi-Largani M, Pourvali-Talatappeh P, Rousta AM, et al.. A review on potential roles of vitamins in incidence, progression, and improvement of multiple sclerosis. eNeurologicalSci. 2018, 10:37-44. 10.1016\/j.ensci.2018.01.007","journal-title":"eNeurologicalSci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.05.022","article-title":"Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial","volume":"285","author":"Toghianifar N","year":"2015","unstructured":"Toghianifar N, Ashtari F, Zarkesh-Esfahani SH, Mansourian M. Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. J Neuroimmunol. 2015, 285:125-8. 10.1016\/j.jneuroim.2015.05.022","journal-title":"J Neuroimmunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-60","article-title":"Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties","volume":"13","author":"Golan D","year":"2013","unstructured":"Golan D, Halhal B, Glass-Marmor L, et al.. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol. 2013, 13:60. 10.1186\/1471-2377-13-60","journal-title":"BMC Neurol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1017\/s0317167100047351","article-title":"Epidemiology of multiple sclerosis: a critical overview","volume":"20","author":"Sadovnick AD","year":"1993","unstructured":"Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci. 1993, 20:17-29. 10.1017\/s0317167100047351","journal-title":"Can J Neurol Sci"},{"key":"ref32","article-title":"The immunological functions of the vitamin D endocrine system","volume":"49","author":"Hayes CE","year":"2003","unstructured":"Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand). 2003, 49:277-300.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-6196(12)65563-3","article-title":"Multiple sclerosis: basic concepts and hypothesis","volume":"64","author":"Rodriguez M","year":"1989","unstructured":"Rodriguez M. Multiple sclerosis: basic concepts and hypothesis. Mayo Clin Proc. 1989, 64:570-6. 10.1016\/s0025-6196(12)65563-3","journal-title":"Mayo Clin Proc"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70243-0","article-title":"Primary-progressive multiple sclerosis","volume":"6","author":"Miller DH","year":"2007","unstructured":"Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007, 6:903-12. 10.1016\/S1474-4422(07)70243-0","journal-title":"Lancet Neurol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/119.2.449","article-title":"Age-adjusted recurrence risks for relatives of patients with multiple sclerosis","volume":"119","author":"Robertson NP","year":"1996","unstructured":"Robertson NP, Fraser M, Deans J, Clayton D, Walker N, Compston DA. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain. 1996, 119:449-55. 10.1093\/brain\/119.2.449","journal-title":"Brain"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1002\/1531-8249(200012)48:6<927::AID-ANA14>3.0.CO;2-F","article-title":"Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group","volume":"48","author":"Ebers GC","year":"2000","unstructured":"Ebers GC, Yee IM, Sadovnick AD, Duquette P. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann Neurol. 2000, 48:927-31.","journal-title":"Ann Neurol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.44.7.1360-b","article-title":"Physical trauma and multiple sclerosis","volume":"44","author":"Poser CM","year":"1994","unstructured":"Poser CM. Physical trauma and multiple sclerosis. Neurology. 1994, 44:1360-2; author reply 1362-4. 10.1212\/wnl.44.7.1360-b","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/0303-8467(94)90042-6","article-title":"The role of trauma in the pathogenesis of multiple sclerosis: a review","volume":"96","author":"Poser CM","year":"1994","unstructured":"Poser CM. The role of trauma in the pathogenesis of multiple sclerosis: a review. Clin Neurol Neurosurg. 1994, 96:103-10. 10.1016\/0303-8467(94)90042-6","journal-title":"Clin Neurol Neurosurg"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2007.08.003","article-title":"Smoking among veterans with multiple sclerosis: prevalence correlates, quit attempts, and unmet need for services","volume":"88","author":"Turner AP","year":"2007","unstructured":"Turner AP, Kivlahan DR, Kazis LE, Haselkorn JK. Smoking among veterans with multiple sclerosis: prevalence correlates, quit attempts, and unmet need for services. Arch Phys Med Rehabil. 2007, 88:1394-9. 10.1016\/j.apmr.2007.08.003","journal-title":"Arch Phys Med Rehabil"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.07.020","article-title":"Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation","volume":"17","author":"Degelman ML","year":"2017","unstructured":"Degelman ML, Herman KM. Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation. Mult Scler Relat Disord. 2017, 17:207-16. 10.1016\/j.msard.2017.07.020","journal-title":"Mult Scler Relat Disord"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis","volume":"74","author":"Marrie RA","year":"2010","unstructured":"Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010, 74:1041-7. 10.1212\/WNL.0b013e3181d6b125","journal-title":"Neurology"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001187","article-title":"Comorbidity increases the risk of hospitalizations in multiple sclerosis","volume":"84","author":"Marrie RA","year":"2015","unstructured":"Marrie RA, Elliott L, Marriott J, Cossoy M, Tennakoon A, Yu N. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology. 2015, 84:350-8. 10.1212\/WNL.0000000000001187","journal-title":"Neurology"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity","volume":"83","author":"Browne P","year":"2014","unstructured":"Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014, 83:1022-4. 10.1212\/WNL.0000000000000768","journal-title":"Neurology"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002469","article-title":"Multiple sclerosis prevalence in the United States commercially insured population","volume":"86","author":"Dilokthornsakul P","year":"2016","unstructured":"Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016, 86:1014-21. 10.1212\/WNL.0000000000002469","journal-title":"Neurology"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70581-6","article-title":"Sex ratio of multiple sclerosis in Canada: a longitudinal study","volume":"5","author":"Orton S-M","year":"2006","unstructured":"Orton S-M, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, Ebers GC. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006, 5:932-6. 10.1016\/S1474-4422(06)70581-6","journal-title":"Lancet Neurol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2011.03.001","article-title":"Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence","volume":"21","author":"Palacios N","year":"2011","unstructured":"Palacios N, Alonso A, Br\u00f8nnum-Hansen H, Ascherio A. Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence. Ann Epidemiol. 2011, 21:536-42. 10.1016\/j.annepidem.2011.03.001","journal-title":"Ann Epidemiol"},{"key":"ref47","article-title":"Multiple sclerosis review","volume":"37","author":"Goldenberg MM","year":"2012","unstructured":"Goldenberg MM. Multiple sclerosis review. P T. 2012, 37:175-84.","journal-title":"P T"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.15586\/codon.multiplesclerosis.2017.ch1","article-title":"The genetics of multiple sclerosis","volume":"3","author":"Didonna A","year":"2017","unstructured":"Didonna A, Oksenberg JR. The genetics of multiple sclerosis. Codon Publications. 2017, 3:16. 10.15586\/codon.multiplesclerosis.2017.ch1","journal-title":"Codon Publications"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws099","article-title":"The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service","volume":"135","author":"Wallin MT","year":"2012","unstructured":"Wallin MT, Culpepper WJ, Coffman P, et al.. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain. 2012, 135:1778-85. 10.1093\/brain\/aws099","journal-title":"Brain"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21141","article-title":"Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors","volume":"61","author":"Ascherio A","year":"2007","unstructured":"Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007, 61:504-13. 10.1002\/ana.21141","journal-title":"Ann Neurol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.5.968","article-title":"The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia","volume":"123","author":"Hammond SR","year":"2000","unstructured":"Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain. 2000, 123:968-74. 10.1093\/brain\/123.5.968","journal-title":"Brain"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2017.4410","article-title":"Multiple sclerosis: pathology, diagnosis and treatments","volume":"13","author":"Huang WJ","year":"2017","unstructured":"Huang WJ, Chen WW, Zhang X. Multiple sclerosis: pathology, diagnosis and treatments. Exp Ther Med. 2017, 13:3163-6. 10.3892\/etm.2017.4410","journal-title":"Exp Ther Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2018.03.006","article-title":"Progress in understanding the pathophysiology of multiple sclerosis","volume":"174","author":"Z\u00e9phir H","year":"2018","unstructured":"Z\u00e9phir H. Progress in understanding the pathophysiology of multiple sclerosis. Rev Neurol (Paris). 2018, 174:358-63. 10.1016\/j.neurol.2018.03.006","journal-title":"Rev Neurol (Paris)"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001136","article-title":"Epidemiology and pathophysiology of multiple sclerosis","volume":"28","author":"Ward M","year":"2022","unstructured":"Ward M, Goldman MD. Epidemiology and pathophysiology of multiple sclerosis. Continuum (Minneap Minn). 2022, 28:988-1005. 10.1212\/CON.0000000000001136","journal-title":"Continuum (Minneap Minn)"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2010.01444.x","article-title":"Pathophysiology of multiple sclerosis and the place of teriflunomide","volume":"124","author":"Gold R","year":"2011","unstructured":"Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011, 124:75-84. 10.1111\/j.1600-0404.2010.01444.x","journal-title":"Acta Neurol Scand"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12671","article-title":"Role of B cells in the pathogenesis of multiple sclerosis","volume":"12","author":"Ochi H","year":"2021","unstructured":"Ochi H. Role of B cells in the pathogenesis of multiple sclerosis. Clin Exp Neuroimmunol. 2021, 12:220-7. 10.1111\/cen3.12671","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin FD","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, et al.. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014, 83:278-86. 10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516643394","article-title":"A significant decrease in diagnosis of primary progressive multiple sclerosis: a cohort study","volume":"22","author":"Westerlind H","year":"2016","unstructured":"Westerlind H, Stawiarz L, Fink K, Hillert J, Manouchehrinia A. A significant decrease in diagnosis of primary progressive multiple sclerosis: a cohort study. Mult Scler. 2016, 22:1071-9. 10.1177\/1352458516643394","journal-title":"Mult Scler"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003028","article-title":"Pediatric multiple sclerosis: clinical features and outcome","volume":"87","author":"Waldman A","year":"2016","unstructured":"Waldman A, Ness J, Pohl D, Simone IL, Anlar B, Amato MP, Ghezzi A. Pediatric multiple sclerosis: clinical features and outcome. Neurology. 2016, 87:S74-81. 10.1212\/WNL.0000000000003028","journal-title":"Neurology"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson AJ","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al.. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018, 17:162-73. 10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30159-5","article-title":"Applying the 2017 McDonald diagnostic criteria for multiple sclerosis","volume":"17","author":"Petzold A","year":"2018","unstructured":"Petzold A. Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol. 2018, 17:496-7. 10.1016\/S1474-4422(18)30159-5","journal-title":"Lancet Neurol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01224-9","article-title":"Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management","volume":"19","author":"Krajnc N","year":"2022","unstructured":"Krajnc N, Bsteh G, Berger T, Mares J, Hartung HP. Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management. Neurotherapeutics. 2022, 19:753-73. 10.1007\/s13311-022-01224-9","journal-title":"Neurotherapeutics"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"82","author":"Lamb YN","year":"2022","unstructured":"Lamb YN. Ocrelizumab: a review in multiple sclerosis. Drugs. 2022, 82:323-34. 10.1007\/s40265-022-01672-9","journal-title":"Drugs"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102454","article-title":"Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis","volume":"46","author":"Vollmer TL","year":"2020","unstructured":"Vollmer TL, Cohen JA, Alvarez E, et al.. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020, 46:102454. 10.1016\/j.msard.2020.102454","journal-title":"Mult Scler Relat Disord"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney DG","year":"2002","unstructured":"Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002, 29:2-9. 10.1053\/sonc.2002.30156","journal-title":"Semin Oncol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles G","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, et al.. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017, 34:2232-73. 10.1007\/s12325-017-0612-x","journal-title":"Adv Ther"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick RA","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, et al.. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006, 354:911-23. 10.1056\/NEJMoa044396","journal-title":"N Engl J Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring","volume":"11","author":"Khoy K","year":"2020","unstructured":"Khoy K, Mariotte D, Defer G, Petit G, Toutirais O, Le Mauff B. Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring. Front Immunol. 2020, 11:549842. 10.3389\/fimmu.2020.549842","journal-title":"Front Immunol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser SL","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al.. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020, 383:546-57. 10.1056\/NEJMoa1917246","journal-title":"N Engl J Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner J","year":"2022","unstructured":"G\u00e4rtner J, Hauser SL, Bar-Or A, et al.. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II. Mult Scler. 2022, 28:1562-75. 10.1177\/13524585221078825","journal-title":"Mult Scler"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01650-7","article-title":"Ofatumumab: a review in relapsing forms of multiple sclerosis","volume":"82","author":"Kang C","year":"2022","unstructured":"Kang C, Blair HA. Ofatumumab: a review in relapsing forms of multiple sclerosis. Drugs. 2022, 82:55-62. 10.1007\/s40265-021-01650-7","journal-title":"Drugs"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser SL","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al.. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017, 376:221-34. 10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban X","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al.. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017, 376:209-20. 10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013247.pub2","article-title":"Ocrelizumab for multiple sclerosis","volume":"5","author":"Lin M","year":"2022","unstructured":"Lin M, Zhang J, Zhang Y, Luo J, Shi S. Ocrelizumab for multiple sclerosis. Cochrane Database Syst Rev. 2022, 5:CD013247. 10.1002\/14651858.CD013247.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2019.1561284","article-title":"Ocrelizumab for the treatment of multiple sclerosis","volume":"19","author":"Bigaut K","year":"2019","unstructured":"Bigaut K, De Seze J, Collongues N. Ocrelizumab for the treatment of multiple sclerosis. Expert Rev Neurother. 2019, 19:97-108. 10.1080\/14737175.2019.1561284","journal-title":"Expert Rev Neurother"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen JA","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, et al.. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012, 380:1819-28. 10.1016\/S0140-6736(12)61769-3","journal-title":"Lancet"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1177\/20552173221135888","article-title":"Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: results from the real-world PRO-ACT study","volume":"8","author":"Wray S","year":"2022","unstructured":"Wray S, Jacques F, Miller TA, et al.. Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: results from the real-world PRO-ACT study. Mult Scler J Exp Transl Clin. 2022, 8:20552173221135888. 10.1177\/20552173221135888","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles AJ","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al.. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012, 380:1829-39. 10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman CH","year":"2006","unstructured":"Polman CH, O'Connor PW, Havrdova E, et al.. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006, 354:899-910. 10.1056\/NEJMoa044397","journal-title":"N Engl J Med"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211003020","article-title":"A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis","volume":"27","author":"Trojano M","year":"2021","unstructured":"Trojano M, Rami\u00f3-Torrent\u00e0 L, Grimaldi LM, et al.. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Mult Scler. 2021, 27:2240-53. 10.1177\/13524585211003020","journal-title":"Mult Scler"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.11.002","article-title":"Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: a double-blind, randomized controlled trial and open-label pharmacokinetic study","volume":"11","author":"Saida T","year":"2017","unstructured":"Saida T, Kira JI, Kishida S, et al.. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: a double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord. 2017, 11:25-31. 10.1016\/j.msard.2016.11.002","journal-title":"Mult Scler Relat Disord"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000095425.84407.39","article-title":"The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"61","author":"Goodin DS","year":"2003","unstructured":"Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003, 61:1332-8. 10.1212\/01.wnl.0000095425.84407.39","journal-title":"Neurology"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418060-00010","article-title":"Mitoxantrone: a review of its use in multiple sclerosis","volume":"18","author":"Scott LJ","year":"2004","unstructured":"Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004, 18:379-96. 10.2165\/00023210-200418060-00010","journal-title":"CNS Drugs"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1002\/med.21567","article-title":"Dimethyl fumarate, a two-edged drug: Current status and future directions","volume":"39","author":"Saidu NEB","year":"2019","unstructured":"Saidu NEB, Kavian N, Leroy K, Jacob C, Nicco C, Batteux F, Alexandre J. Dimethyl fumarate, a two-edged drug: Current status and future directions. Med Res Rev. 2019, 39:1923-52. 10.1002\/med.21567","journal-title":"Med Res Rev"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.190132","article-title":"Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway","volume":"341","author":"Scannevin RH","year":"2012","unstructured":"Scannevin RH, Chollate S, Jung MY, et al.. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012, 341:274-84. 10.1124\/jpet.111.190132","journal-title":"J Pharmacol Exp Ther"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107710","article-title":"Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature","volume":"219","author":"Dello Russo C","year":"2021","unstructured":"Dello Russo C, Scott KA, Pirmohamed M. Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature. Pharmacol Ther. 2021, 219:107710. 10.1016\/j.pharmthera.2020.107710","journal-title":"Pharmacol Ther"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi PA","year":"2014","unstructured":"Calabresi PA, Radue E-W, Goodin D, et al.. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014, 13:545-56. 10.1016\/S1474-4422(14)70049-3","journal-title":"Lancet Neurol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-65","article-title":"Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial","volume":"14","author":"Laroni A","year":"2014","unstructured":"Laroni A, Brogi D, Morra VB, et al.. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol. 2014, 14:65. 10.1186\/1471-2377-14-65","journal-title":"BMC Neurol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi G","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, et al.. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019, 18:1009-20. 10.1016\/S1474-4422(19)30239-X","journal-title":"Lancet Neurol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen JA","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW, et al.. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019, 18:1021-33. 10.1016\/S1474-4422(19)30238-8","journal-title":"Lancet Neurol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-022-03137-2","article-title":"Ozanimod-dependent activation of SIRT3\/NF-\u03bab\/AIM2 pathway attenuates secondary injury after intracerebral hemorrhage","author":"Li X","year":"2022","unstructured":"Li X, Zhang H, Zheng W, Sun J, Wang L, He Z. Ozanimod-dependent activation of SIRT3\/NF-\u03bab\/AIM2 pathway attenuates secondary injury after intracerebral hemorrhage. Mol Neurobiol. 2022, 10.1007\/s12035-022-03137-2","journal-title":"Mol Neurobiol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos L","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, et al.. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018, 391:1263-73. 10.1016\/S0140-6736(18)30475-6","journal-title":"Lancet"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00771-z","article-title":"Siponimod: a review in secondary progressive multiple sclerosis","volume":"34","author":"Scott LJ","year":"2020","unstructured":"Scott LJ. Siponimod: a review in secondary progressive multiple sclerosis. CNS Drugs. 2020, 34:1191-200. 10.1007\/s40263-020-00771-z","journal-title":"CNS Drugs"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201911910110","article-title":"The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis [Article in Russian]","volume":"119","author":"Evdoshenko EP","year":"2019","unstructured":"Evdoshenko EP, Neofidov NA, Bakhtiyarova KZ, et al.. The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2019, 119:110-19. 10.17116\/jnevro201911910110","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni G","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al.. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010, 362:416-26. 10.1056\/NEJMoa0902533","journal-title":"N Engl J Med"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook S","year":"2011","unstructured":"Cook S, Vermersch P, Comi G, et al.. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011, 17:578-93. 10.1177\/1352458510391344","journal-title":"Mult Scler"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1586\/ern.10.12","article-title":"Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis","volume":"10","author":"Sipe JC","year":"2010","unstructured":"Sipe JC. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert Rev Neurother. 2010, 10:365-75. 10.1586\/ern.10.12","journal-title":"Expert Rev Neurother"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01229-3","article-title":"Dimethyl fumarate: a review in relapsing-remitting MS","volume":"79","author":"Blair HA","year":"2019","unstructured":"Blair HA. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2019, 79:1965-76. 10.1007\/s40265-019-01229-3","journal-title":"Drugs"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001037","article-title":"Dimethyl fumarate treatment in patients with primary progressive multiple sclerosis: a randomized, controlled trial","volume":"8","author":"H\u00f8jsgaard Chow H","year":"2021","unstructured":"H\u00f8jsgaard Chow H, Talbot J, Lundell H, et al.. Dimethyl fumarate treatment in patients with primary progressive multiple sclerosis: a randomized, controlled trial. Neurol Neuroimmunol Neuroinflamm. 2021, 8:e1037. 10.1212\/NXI.0000000000001037","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos L","year":"2010","unstructured":"Kappos L, Radue EW, O'Connor P, et al.. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010, 362:387-401. 10.1056\/NEJMoa0909494","journal-title":"N Engl J Med"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2022.18.6.663","article-title":"Safety and temporal pattern of the lymphocyte count during fingolimod therapy in patients with multiple sclerosis: real-world Korean experience","volume":"18","author":"Huh SY","year":"2022","unstructured":"Huh SY, Kim SH, Kim KH, et al.. Safety and temporal pattern of the lymphocyte count during fingolimod therapy in patients with multiple sclerosis: real-world Korean experience. J Clin Neurol. 2022, 18:663-70. 10.3988\/jcn.2022.18.6.663","journal-title":"J Clin Neurol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor P","year":"2011","unstructured":"O'Connor P, Wolinsky JS, Confavreux C, et al.. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011, 365:1293-303. 10.1056\/NEJMoa1014656","journal-title":"N Engl J Med"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.50.3.701","article-title":"Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group","volume":"50","author":"Johnson KP","year":"1998","unstructured":"Johnson KP, Brooks BR, Cohen JA, et al.. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998, 50:701-8. 10.1212\/wnl.50.3.701","journal-title":"Neurology"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.2165\/11588120-000000000-00000","article-title":"Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action","volume":"25","author":"Lalive PH","year":"2011","unstructured":"Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011, 25:401-14. 10.2165\/11588120-000000000-00000","journal-title":"CNS Drugs"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs LD","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA, et al.. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996, 39:285-94. 10.1002\/ana.410390304","journal-title":"Ann Neurol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.49.2.358","article-title":"Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"49","author":"Rudick RA","year":"1997","unstructured":"Rudick RA, Goodkin DE, Jacobs LD, et al.. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology. 1997, 49:358-63. 10.1212\/wnl.49.2.358","journal-title":"Neurology"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0245-z","article-title":"Glatiramer acetate 40 mg\/ml in relapsing-remitting multiple sclerosis: a review","volume":"29","author":"McKeage K","year":"2015","unstructured":"McKeage K. Glatiramer acetate 40 mg\/ml in relapsing-remitting multiple sclerosis: a review. CNS Drugs. 2015, 29:425-32. 10.1007\/s40263-015-0245-z","journal-title":"CNS Drugs"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004678.pub2","article-title":"Glatiramer acetate for multiple sclerosis","author":"La Mantia L","year":"2010","unstructured":"La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev. 2010, CD004678. 10.1002\/14651858.CD004678.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi PA","year":"2014","unstructured":"Calabresi PA, Kieseier BC, Arnold DL, et al.. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014, 13:657-65. 10.1016\/S1474-4422(14)70068-7","journal-title":"Lancet Neurol"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0227-1","article-title":"Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis","volume":"29","author":"Hoy SM","year":"2015","unstructured":"Hoy SM. Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs. 2015, 29:171-9. 10.1007\/s40263-015-0227-1","journal-title":"CNS Drugs"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux C","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, et al.. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014, 13:247-56. 10.1016\/S1474-4422(13)70308-9","journal-title":"Lancet Neurol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009882.pub3","article-title":"Teriflunomide for multiple sclerosis","volume":"3","author":"He D","year":"2016","unstructured":"He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L. Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev. 2016, 3:CD009882. 10.1002\/14651858.CD009882.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon \u03b2-1a in relapsing\/remitting multiple sclerosis","volume":"352","author":"Ebers GC","year":"1998","unstructured":"Ebers GC. Randomised double-blind placebo-controlled study of interferon \u03b2-1a in relapsing\/remitting multiple sclerosis. Lancet. 1998, 352:1498-504. 10.1016\/S0140-6736(98)03334-0","journal-title":"Lancet"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00822-z","article-title":"Interferons and multiple sclerosis: lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a (Avonex)","volume":"35","author":"Cohan SL","year":"2021","unstructured":"Cohan SL, Hendin BA, Reder AT, Smoot K, Avila R, Mendoza JP, Weinstock-Guttman B. Interferons and multiple sclerosis: lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a (Avonex). CNS Drugs. 2021, 35:743-67. 10.1007\/s40263-021-00822-z","journal-title":"CNS Drugs"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group","volume":"43","year":"1993","unstructured":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993, 43.655-61. 10.1212\/wnl.43.4.655","journal-title":"Neurology"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1097\/01376517-199402000-00010","article-title":"Betaseron: the new MS treatment","volume":"26","author":"Kelley CL","year":"1994","unstructured":"Kelley CL, Smeltzer SC. Betaseron: the new MS treatment. J Neurosci Nurs. 1994, 26:52-6. 10.1097\/01376517-199402000-00010","journal-title":"J Neurosci Nurs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131339-an-overview-of-the-history-pathophysiology-and-pharmacological-interventions-of-multiple-sclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:53:38Z","timestamp":1707490418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131339-an-overview-of-the-history-pathophysiology-and-pharmacological-interventions-of-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,2]]},"references-count":116,"URL":"https:\/\/doi.org\/10.7759\/cureus.33242","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,2]]}}}